Skip to content

Clinical Evaluation of DAILIES TOTAL 1® Performance in a Japanese Population

Clinical Evaluation of DAILIES TOTAL 1® in Japanese Population - Comparison of Lens Centration Between DAILIES TOTAL 1® and 1-DAY ACUVUE® TruEye®

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02710292
Enrollment
104
Registered
2016-03-16
Start date
2016-04-25
Completion date
2016-09-14
Last updated
2018-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Error

Brief summary

The purpose of this study is to compare DAILIES TOTAL1® (DT1) to 1-DAY ACUVUE® TruEye® (TE) for Investigator-rated successful lens centration in Japanese population.

Interventions

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Must sign an informed consent form; * Habitual current daily disposable soft contact lenses wearer; * Symptoms of contact lens discomfort as defined by the Symptomatology (Eligibility) Questionnaire; * Lenses within the power range specified in the protocol; * Vision correctable to 20/25 or 0.1 logMAR (logarithmic minimum angle of resolution) or better in each eye at distance with pre-study contact lenses at Visit1; * Acceptable lens fit with both study contact lenses; * Willing to wear lenses every day or at least for a minimum of 10 days, 6 hours per day, every day if possible and attend all study visits; * Other protocol-specified inclusion criteria may apply.

Exclusion criteria

* Currently wearing DT1 or TE sphere lenses; * Ocular anterior segment infection, inflammation, abnormality, or active disease that would contraindicate contact lens wear; * Use of systemic or ocular medications in which contact lens wear could be contraindicated as determined by the investigator; * Eye injury or surgery within 12 weeks immediately prior to enrollment; * History of herpetic keratitis, ocular surgery or irregular cornea; * Prior refractive surgery; * Monocular (only 1 eye with functional vision) or fit with only 1 lens; * Participation in any clinical trial within 30 days of the enrollment visit; * Other protocol-specified

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Subjects With Investigator-rated Lens Centration of Optimal After 10 Days of WearDay 10, each productLens centration was assessed by the investigator on a 5-point scale, where 0=Optimal and 4=Severe decentration (with corneal exposure). Both eyes contributed to the analysis.

Countries

Japan

Participant flow

Recruitment details

Subjects were recruited from 6 study sites located in Japan.

Pre-assignment details

Of the 104 subjects, 5 were exited as screen failures prior to being enrolled. This reporting group includes all enrolled subjects (99).

Participants by arm

ArmCount
Overall
Delefilcon A and narafilcon A contact lenses worn during Period 1 and Period 2 in a crossover assignment.
99
Total99

Withdrawals & dropouts

PeriodReasonFG000FG001
Period 1, First 10 Days of WearAdverse Event01
Period 1, First 10 Days of WearWithdrawal by Subject12

Baseline characteristics

CharacteristicOverall
Age, Continuous39.9 years
STANDARD_DEVIATION 9.7
Sex: Female, Male
Female
72 Participants
Sex: Female, Male
Male
27 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
0 / 1047 / 9623 / 98
serious
Total, serious adverse events
0 / 1040 / 960 / 98

Outcome results

Primary

Percentage of Subjects With Investigator-rated Lens Centration of Optimal After 10 Days of Wear

Lens centration was assessed by the investigator on a 5-point scale, where 0=Optimal and 4=Severe decentration (with corneal exposure). Both eyes contributed to the analysis.

Time frame: Day 10, each product

Population: This analysis population includes all subjects who used the study device and in whom data after the use of the study device were available (Full Analysis Set).

ArmMeasureValue (NUMBER)
Dailies Total1Percentage of Subjects With Investigator-rated Lens Centration of Optimal After 10 Days of Wear89.5 percentage of subjects
TruEyePercentage of Subjects With Investigator-rated Lens Centration of Optimal After 10 Days of Wear47.4 percentage of subjects

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026